MERIT40 Is an Akt Substrate that Promotes Resolution of DNA Damage Induced by Chemotherapy

Cell Reports

Volumn 11, Issue 9, 2015, Pages 1358-1366

  Brown, Kristin K ^a   Montaser Kouhsari, Laleh ^a   Beck, Andrew H ^a   Toker, Alex ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; DOXORUBICIN; HISTONE H2AX; MERIT40; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TANKYRASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BABAM1 PROTEIN, HUMAN; ENZYME INHIBITOR; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; BREAST TUMOR; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TISSUE MICROARRAY; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TISSUE ARRAY ANALYSIS;

EID: 84930756708     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.05.004     Document Type: Article

References (29)

1. Antoniou A.C., Wang X., Fredericksen Z.S., McGuffog L., Tarrell R., Sinilnikova O.M., Healey S., Morrison J., Kartsonaki C., Lesnick T., et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat. Genet. 2010, 42:885-892. EMBRACE, GEMO Study CollaboratorsGEMO Study Collaborators, HEBONHEBON, kConFabkConFab, SWE-BRCASWE-BRCA, MOD SQUADMOD SQUAD, GENICAGENICA.
2. Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 2011, 16(Suppl 1):12-19.
3. Bezler M., Hengstler J.G., Ullrich A. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol. Oncol. 2012, 6:516-529.
4. Bian C., Wu R., Cho K., Yu X. Loss of BRCA1-A complex function in RAP80 null tumor cells. PLoS ONE 2012, 7:e40406.
5. Bolton K.L., Tyrer J., Song H., Ramus S.J., Notaridou M., Jones C., Sher T., Gentry-Maharaj A., Wozniak E., Tsai Y.Y., et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat. Genet. 2010, 42:880-884. Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer)Australian Cancer Study (Ovarian Cancer), Ovarian Cancer Association ConsortiumOvarian Cancer Association Consortium.
6. Bozulic L., Surucu B., Hynx D., Hemmings B.A. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol. Cell 2008, 30:203-213.
7. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
8. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28:1075-1083.
9. Dienstmann R., Rodon J., Serra V., Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol. Cancer Ther. 2014, 13:1021-1031.
10. Dregalla R.C., Zhou J., Idate R.R., Battaglia C.L., Liber H.L., Bailey S.M. Regulatory roles of tankyrase 1 at telomeres and in DNA repair: suppression of T-SCE and stabilization of DNA-PKcs. Aging (Albany, N.Y. Online) 2010, 2:691-708.
11. Elloul S., Kedrin D., Knoblauch N.W., Beck A.H., Toker A. The adherens junction protein afadin is an AKT substrate that regulates breast cancer cell migration. Mol. Cancer Res. 2014, 12:464-476.
12. Feng L., Huang J., Chen J. MERIT40 facilitates BRCA1 localization and DNA damage repair. Genes Dev. 2009, 23:719-728.
13. Guettler S., LaRose J., Petsalaki E., Gish G., Scotter A., Pawson T., Rottapel R., Sicheri F. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease. Cell 2011, 147:1340-1354.
14. Hu X., Kim J.A., Castillo A., Huang M., Liu J., Wang B. NBA1/MERIT40 and BRE interaction is required for the integrity of two distinct deubiquitinating enzyme BRCC36-containing complexes. J. Biol. Chem. 2011, 286:11734-11745.
15. Hu Y., Petit S.A., Ficarro S.B., Toomire K.J., Xie A., Lim E., Cao S.A., Park E., Eck M.J., Scully R., et al. PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair. Cancer Discov. 2014, 4:1430-1447.
16. Isakoff S.J., Engelman J.A., Irie H.Y., Luo J., Brachmann S.M., Pearline R.V., Cantley L.C., Brugge J.S. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005, 65:10992-11000.
17. Kim H., Chen J., Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 2007, 316:1202-1205.
18. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
19. Moritz A., Li Y., Guo A., Villén J., Wang Y., MacNeill J., Kornhauser J., Sprott K., Zhou J., Possemato A., et al. Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci. Signal. 2010, 3:ra64.
20. Paplomata E., O'Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther. Adv. Med. Oncol. 2014, 6:154-166.
21. Rodon J., Dienstmann R., Serra V., Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 2013, 10:143-153.
22. Shao G., Patterson-Fortin J., Messick T.E., Feng D., Shanbhag N., Wang Y., Greenberg R.A. MERIT40 controls BRCA1-Rap80 complex integrity and recruitment to DNA double-strand breaks. Genes Dev. 2009, 23:740-754.
23. Sobhian B., Shao G., Lilli D.R., Culhane A.C., Moreau L.A., Xia B., Livingston D.M., Greenberg R.A. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007, 316:1198-1202.
24. Tewey K.M., Rowe T.C., Yang L., Halligan B.D., Liu L.F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984, 226:466-468.
25. Wallin J.J., Guan J., Prior W.W., Edgar K.A., Kassees R., Sampath D., Belvin M., Friedman L.S. Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer. Sci. Transl. Med. 2010, 2:48ra66.
26. Wang B., Matsuoka S., Ballif B.A., Zhang D., Smogorzewska A., Gygi S.P., Elledge S.J. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007, 316:1194-1198.
27. Wang B., Hurov K., Hofmann K., Elledge S.J. NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. Genes Dev. 2009, 23:729-739.
28. Wu J., Liu C., Chen J., Yu X. RAP80 protein is important for genomic stability and is required for stabilizing BRCA1-A complex at DNA damage sites in vivo. J. Biol. Chem. 2012, 287:22919-22926.
29. Xu N., Lao Y., Zhang Y., Gillespie D.A. Akt: a double-edged sword in cell proliferation and genome stability. J. Oncol. 2012, 2012:951724.